Mark C. Schneyer is CFO & VP at ACADIA PHARMACEUTICALS INC (ACAD). They have made 15 open-market trades across 1 company since 2022, most recently 2026-08-06.
CIK 0001899977
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ACAD | 67,828 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACAD | SELL · 10b5-1 | 2026-08-05 | 2026-08-07 | $29.16 | $587K | +3.5% | -5.6% | — |
| ACAD | SELL · 10b5-1 | 2026-05-04 | 2026-05-05 | $21.79 | $76K | -5.5% | -4.1% | +13.1% |
| ACAD | SELL · 10b5-1 | 2026-04-07 | 2026-04-07 | $22.20 | $60K | -3.0% | -1.2% | +12.8% |
| ACAD | SELL · 10b5-1 | 2026-03-25 | 2026-03-26 | $21.55 | $160K | +6.2% | +4.9% | +9.9% |
| ACAD | SELL | 2025-11-18 | 2025-11-19 | $23.69 | $486K | +8.3% | +15.6% | -2.3% |
| ACAD | SELL | 2025-09-15 | 2025-09-16 | $23.65 | $165K | -12.5% | -14.3% | +13.3% |
| ACAD | SELL · 10b5-1 | 2025-08-18 | 2025-08-19 | $25.18 | $554K | +4.8% | -0.2% | -3.2% |
| ACAD | SELL · 10b5-1 | 2025-05-16 | 2025-05-19 | $25.00 | $50K | -1.3% | +5.0% | +14.7% |
| ACAD | SELL | 2025-05-02 | 2025-05-02 | $14.60 | $102K | +16.3% | +45.4% | +61.4% |
| ACAD | SELL · 10b5-1 | 2025-04-08 | 2025-04-08 | $14.82 | $40K | +4.4% | +22.9% | +51.5% |
| ACAD | SELL | 2025-03-26 | 2025-03-26 | $17.05 | $108K | -14.6% | -13.9% | +31.1% |
| ACAD | SELL · 10b5-1 | 2025-02-24 | 2025-02-25 | $19.96 | $15K | -8.0% | -9.9% | +16.3% |
| ACAD | SELL | 2024-11-19 | 2024-11-19 | $16.81 | $345K | +2.2% | +3.0% | +21.5% |
| ACAD | SELL | 2024-08-19 | 2024-08-20 | $15.28 | $297K | +5.9% | +4.9% | +8.7% |
| ACAD | SELL · 10b5-1 | 2024-06-10 | 2024-06-11 | $14.79 | $14K | +3.7% | +15.3% | +3.0% |
| ACAD | SELL | 2024-05-02 | 2024-05-03 | $16.94 | $119K | -11.8% | -10.9% | +10.7% |
| ACAD | SELL · 10b5-1 | 2024-04-08 | 2024-04-09 | $17.87 | $49K | -5.1% | -14.2% | -7.9% |
| ACAD | SELL | 2024-03-27 | 2024-03-27 | $17.90 | $195K | -0.3% | -8.2% | -14.3% |
| ACAD | SELL · 10b5-1 | 2024-02-26 | 2024-02-27 | $24.67 | $19K | -4.9% | -25.0% | -38.8% |
| ACAD | SELL | 2023-11-20 | 2023-11-21 | $22.64 | $231K | +2.6% | +32.6% | +11.6% |
| ACAD | SELL · 10b5-1 | 2023-08-21 | 2023-08-23 | $29.00 | $290K | -4.1% | -18.0% | -21.9% |
| ACAD | SELL | 2023-06-08 | 2023-06-12 | $25.02 | $24K | -0.5% | +5.0% | +10.1% |
| ACAD | SELL | 2023-05-17 | 2023-05-19 | $22.50 | $344K | -1.7% | -2.0% | +18.8% |
| ACAD | SELL | 2023-04-06 | 2023-04-07 | $18.16 | $35K | +10.4% | +18.8% | +33.6% |
| ACAD | SELL | 2023-02-24 | 2023-02-27 | $18.78 | $11K | +3.3% | -4.4% | +19.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.